Companion Diagnostics for Oncology

Companion Diagnostics for Oncology Market Outlook

The global companion diagnostics for oncology market is poised to reach a value of approximately USD 7.5 billion by 2035, reflecting a remarkable compound annual growth rate (CAGR) of around 14.2% during the forecast period of 2025 to 2035. This growth is driven by the increasing incidence of cancer, advancements in diagnostic technologies, and a growing emphasis on personalized medicine, which tailors treatment based on individual patient profiles. Furthermore, the rising awareness of the importance of early detection and treatment of cancers has led to greater demand for companion diagnostics, particularly in oncology. The integration of biomarkers into therapeutic decision-making processes is also fueling the market's expansion, as clinicians seek to optimize treatment efficacy and minimize adverse effects for patients.

Growth Factor of the Market

The companion diagnostics market for oncology is driven by several key factors that collectively enhance its growth potential. Firstly, the increasing prevalence of various cancers—such as breast, lung, and colorectal cancer—has spurred the demand for diagnostics that can accurately identify specific genetic markers associated with these diseases. Secondly, advancements in technology, particularly in genomics and proteomics, have led to the development of more sophisticated diagnostic tools, which are capable of providing detailed insights into the molecular makeup of tumors. Thirdly, the pharmaceutical industry is increasingly focusing on personalized medicine, where companion diagnostics play a critical role in determining the most effective therapies for individual patients, thereby improving treatment outcomes. Additionally, regulatory bodies are actively supporting the integration of companion diagnostics into clinical practice, further propelling market growth. Lastly, collaborations between diagnostic companies and pharmaceutical firms are fostering innovation and expanding the range of available companion diagnostic tests.

Key Highlights of the Market

• The market is expected to achieve a CAGR of 14.2% from 2025 to 2035.
• Increasing emphasis on personalized medicine drives demand for companion diagnostics.
• Technological advancements in diagnostics significantly enhance testing capabilities.
• The growing incidence of cancer worldwide contributes to market expansion.
• Regulatory support for companion diagnostics boosts adoption rates among healthcare providers.

By Product Type

PCR-Based Tests:

PCR-based tests are among the most widely utilized methodologies in the companion diagnostics market for oncology. These tests leverage the polymerase chain reaction (PCR) technique to amplify specific DNA sequences, allowing for the detection of genetic mutations that may influence treatment decisions. The high sensitivity and specificity offered by PCR make it an ideal choice for identifying actionable mutations in various cancers, particularly in instances where tissue samples may be limited. As the focus on targeted therapies continues to grow, the role of PCR-based tests in identifying patient eligibility for such treatments becomes increasingly paramount. Moreover, innovations such as digital PCR are enhancing the accuracy and efficiency of these tests, further solidifying their position within the market.

FISH-Based Tests:

Fluorescence in situ hybridization (FISH) tests utilize fluorescent probes that bind to specific DNA sequences, enabling the visualization of genetic abnormalities within cancer cells. This method is particularly valuable in identifying chromosomal alterations, such as amplifications or translocations, which are critical in the diagnosis and prognostication of various cancers. FISH testing is commonly employed in cases of hematological malignancies and solid tumors, offering insights into disease progression and potential therapeutic targets. The growing understanding of the genetic underpinnings of cancer has enhanced the relevance of FISH-based tests in clinical practice, leading to their increasing adoption as companion diagnostics that guide treatment decisions and monitor patient responses.

Immunohistochemistry Tests:

Immunohistochemistry (IHC) tests are pivotal in assessing the expression of specific proteins within tumor tissues, providing crucial information about the malignancy's characteristics. These tests utilize antibodies to detect target proteins, allowing healthcare professionals to understand tumor biology better and make informed treatment choices. For instance, IHC testing is essential in identifying hormone receptor status in breast cancer or assessing HER2 overexpression, which directly influences treatment strategies. As the landscape of oncology continues to evolve, the significance of IHC tests as companion diagnostics cannot be overstated, as they help clinicians tailor therapies based on the unique molecular profile of each patient's tumor.

Next-Generation Sequencing Tests:

Next-generation sequencing (NGS) tests represent one of the most transformative advancements in the field of companion diagnostics for oncology. NGS allows for comprehensive analysis of genomic alterations across a wide array of cancer-related genes, offering insights into mutations, copy number variations, and transcriptomic changes. This technology not only aids in identifying actionable mutations that can inform treatment decisions but also facilitates the development of novel therapies tailored to specific genetic profiles. As healthcare shifts towards a more personalized approach, the demand for NGS tests in oncology will continue to grow, driven by their ability to uncover intricate details about tumor genomics that traditional testing methods may miss.

In Situ Hybridization Tests:

In situ hybridization (ISH) tests are instrumental in detecting and localizing specific nucleic acid sequences within fixed tissues, providing valuable insights into the genetic characteristics of tumors. These tests are particularly effective in identifying gene amplifications and translocations, which are essential for accurate diagnosis and treatment planning in oncology. ISH techniques, including RNA in situ hybridization, allow clinicians to visualize the expression of target genes directly within the tissue context, aiding in the assessment of tumor heterogeneity. As the understanding of cancer genetics deepens, the role of ISH tests as companion diagnostics becomes increasingly significant, helping to guide therapeutic interventions and monitor treatment responses.

By Application

Breast Cancer:

Breast cancer remains one of the most common malignancies globally, making companion diagnostics in this area particularly crucial. Tests such as HER2 status assessment via IHC or FISH are pivotal in determining eligibility for targeted therapies like trastuzumab. The integration of genetic testing to identify BRCA mutations is also on the rise, guiding decisions around prevention, treatment, and surveillance strategies. As research continues to unveil the molecular complexities of breast cancer, the demand for companion diagnostics tailored to this application is expected to grow significantly, enhancing treatment efficacy and patient outcomes.

Lung Cancer:

Lung cancer is a leading cause of cancer-related mortality, and the role of companion diagnostics in this domain is critical. Tests that identify mutations in genes such as EGFR, ALK, and ROS1 have transformed the treatment landscape, enabling the use of targeted therapies that significantly improve patient survival rates. The emergence of liquid biopsy techniques for detecting circulating tumor DNA is further expanding the scope of companion diagnostics in lung cancer, allowing for real-time monitoring of disease progression and treatment response. As the understanding of lung cancer's molecular biology deepens, the market for companion diagnostics in this application is expected to expand substantially.

Colorectal Cancer:

In colorectal cancer, companion diagnostics are essential for identifying mutations in genes like KRAS and BRAF, which can dictate the appropriateness of targeted therapies. This application is particularly pertinent, given the rising incidence of colorectal cancer worldwide. The implementation of biomarker testing is vital for selecting patients who may benefit from treatments such as anti-EGFR monoclonal antibodies, leading to improved clinical outcomes. As awareness of the importance of molecular profiling in managing colorectal cancer grows, the demand for companion diagnostics within this application is projected to increase significantly.

Melanoma:

Melanoma is characterized by its aggressive nature and the importance of identifying specific mutations, such as BRAF, which can guide targeted therapy decisions. Companion diagnostics play a fundamental role in stratifying patients for treatments like BRAF inhibitors, significantly impacting survival rates. Furthermore, the increasing use of immunotherapies has heightened the need for biomarkers that predict response, making companion diagnostics an integral component of melanoma management. The growing recognition of the need for personalized approaches in melanoma treatment is expected to drive the market for companion diagnostics in this application.

Others:

In addition to the predominant cancer types, companion diagnostics play a role in various other malignancies, including prostate cancer and hematological cancers. The development of tests tailored to specific biomarkers in these cancers is essential for guiding treatment decisions and ensuring optimal patient management. As research continues to uncover novel biomarkers and therapeutic targets, the market for companion diagnostics in these 'other' applications is likely to see considerable growth. The ongoing exploration of the genetic landscape of diverse cancers will further enhance the relevance and application of companion diagnostics across the oncology spectrum.

By Distribution Channel

Hospitals:

Hospitals are critical distribution channels for companion diagnostics, as they are often where initial diagnosis and treatment planning occurs. Within hospital settings, companion diagnostics are integrated into clinical workflows, enabling healthcare providers to utilize these tests in real-time for patient management. The demand for companion diagnostics in hospitals is bolstered by the increasing emphasis on personalized medicine, as patients benefit from tailored treatment strategies based on specific biomarkers. Additionally, hospitals are equipped with the necessary infrastructure and expertise to handle complex diagnostic tests, making them a key player in the companion diagnostics market.

Diagnostic Laboratories:

Diagnostic laboratories play a vital role in the companion diagnostics ecosystem, serving as specialized facilities that conduct a wide range of tests to support oncological care. These laboratories are often equipped with advanced technologies, such as NGS and PCR, allowing them to perform complex analyses with high accuracy. The increasing reliance on diagnostic laboratories for companion testing is driven by the need for timely and precise information that informs treatment decisions. As the volume of tests grows, diagnostic laboratories are expected to expand their capabilities further, ensuring they can meet the demands of healthcare providers and patients alike.

Research Institutes:

Research institutes are crucial in advancing the field of companion diagnostics through innovation and development. These institutions often focus on identifying novel biomarkers and developing new testing methodologies that can enhance patient care in oncology. Collaborations between research institutes and diagnostics companies are fostering the creation of cutting-edge tests that can be utilized in clinical settings. As research continues to unveil intricate details about cancer biology, the role of research institutes in the companion diagnostics market will become increasingly significant, driving the discovery of new applications and improving existing testing platforms.

Others:

In addition to hospitals and diagnostic laboratories, other distribution channels, such as online platforms and retail pharmacies, are emerging as important avenues for companion diagnostics. These channels provide patients with greater access to testing options, especially in regions with limited healthcare facilities. The trend towards consumer-driven healthcare is encouraging the development of more accessible companion diagnostic tests, allowing patients to engage more actively in their health management. As the market evolves, these alternative distribution channels are expected to play a growing role in the companion diagnostics landscape, broadening access and improving patient outcomes.

By Biomarker Type

EGFR:

EGFR (epidermal growth factor receptor) is a critical biomarker in the companion diagnostics market, particularly for non-small cell lung cancer (NSCLC). The identification of EGFR mutations plays a pivotal role in determining patient eligibility for targeted therapies, such as tyrosine kinase inhibitors. As the understanding of EGFR's role in tumor progression deepens, the demand for companion diagnostics that assess EGFR status is expected to grow significantly. Moreover, advancements in testing technologies, such as liquid biopsies, are enhancing the ability to monitor EGFR alterations in real-time, contributing to improved patient management and therapeutic outcomes.

ALK:

ALK (anaplastic lymphoma kinase) is another essential biomarker used in companion diagnostics, particularly in lung cancer. The presence of ALK rearrangements is a significant indicator of responsiveness to ALK inhibitors, providing a targeted approach that can lead to more effective treatments. As the landscape of lung cancer therapies continues to evolve, the need for companion diagnostics that accurately identify ALK alterations is paramount. The integration of these tests into clinical practice not only aids in selecting appropriate therapies but also reinforces the growing emphasis on precision medicine in oncology.

KRAS:

KRAS mutations are among the most common genetic alterations in various cancers, particularly colorectal cancer and pancreatic cancer. The identification of KRAS status through companion diagnostics is essential for guiding treatment decisions, especially regarding anti-EGFR therapies. As research advances, the understanding of KRAS biology is expanding, leading to the development of targeted therapies aimed at this challenging biomarker. The increasing prevalence of KRAS mutations in oncology underscores the necessity of companion diagnostics in determining patient eligibility for specific treatments and improving clinical outcomes.

HER2:

HER2 (human epidermal growth factor receptor 2) is a well-established biomarker in breast cancer, serving as a critical determinant for the use of targeted therapies, such as trastuzumab. Companion diagnostics that assess HER2 status are crucial for identifying patients who are most likely to benefit from these treatments. The ongoing research into HER2-targeted therapies and their implications for various cancers is further solidifying the importance of HER2 testing in companion diagnostics. As the understanding of HER2's role in tumor biology expands, the market for companion diagnostics focusing on this biomarker is expected to grow significantly, enhancing patient outcomes and treatment efficacy.

BRAF:

BRAF mutations are primarily associated with melanoma but are also found in other cancers such as colorectal cancer. The presence of specific BRAF mutations, such as BRAF V600E, is critical for determining eligibility for targeted therapies, including BRAF inhibitors. Companion diagnostics that identify BRAF mutations play a vital role in guiding treatment decisions and improving patient outcomes. As research continues to uncover the complexities of BRAF-driven cancers and the development of new therapies targeting this biomarker progresses, the demand for companion diagnostics focused on BRAF is expected to rise, further bolstering the market.

By Region

The companion diagnostics for oncology market is witnessing substantial growth across various regions, with North America leading the charge due to its advanced healthcare infrastructure and significant investment in research and development. The North American market is projected to account for a considerable share, driven by the rising incidence of cancer and the growing adoption of personalized medicine. The region's CAGR is estimated at around 13.5% over the forecast period, reflecting the increasing integration of companion diagnostics into clinical pathways. Furthermore, the presence of key players and a favorable regulatory environment contribute to the region's dominance in the market.

In Europe, the companion diagnostics market is also experiencing robust growth, albeit at a slightly lower CAGR compared to North America. The European market is expected to capitalize on the rising awareness surrounding personalized medicine and the growing emphasis on biomarker-driven therapies. With a diverse range of cancer types being addressed, the market is projected to expand significantly as healthcare providers increasingly recognize the value of companion diagnostics in improving treatment outcomes for patients. Additionally, Asia Pacific is emerging as a rapidly growing region, driven by the rising incidence of cancer, increased healthcare spending, and advancements in diagnostic technologies, making it a key area for future growth.

Opportunities

The companion diagnostics market for oncology is poised for significant opportunities, primarily driven by advancements in technology and the increasing emphasis on personalized medicine. The continuous evolution of genomic technologies, such as next-generation sequencing, presents a myriad of avenues for developing novel companion diagnostics that can cater to diverse cancer types. As researchers discover new biomarkers associated with various malignancies, there will be an escalating demand for diagnostic tests that can accurately identify these targets. Furthermore, the integration of artificial intelligence and machine learning into diagnostic processes holds the potential to revolutionize how companion diagnostics are developed and utilized, enabling more precise and efficient patient care. This technological progression not only enhances the testing capabilities but also promises to improve patient outcomes and reduce healthcare costs, making it a compelling opportunity for stakeholders in this market.

Moreover, the collaborative landscape between pharmaceutical companies and diagnostic manufacturers is evolving, providing a fertile ground for innovation in companion diagnostics. As the demand for targeted therapies continues to rise, the need for associated diagnostic tests that can identify suitable patient populations is becoming increasingly critical. Strategic partnerships and alliances can expedite the development and commercialization of companion diagnostics, ensuring that healthcare providers have access to the latest advancements in testing technology. Additionally, as regulatory bodies continue to embrace personalized medicine, there is an opportunity for expedited approvals of companion diagnostics, enhancing their availability in clinical settings. This combined momentum creates a robust environment for growth and innovation within the companion diagnostics market.

Threats

Despite the promising growth potential of the companion diagnostics market, several threats could impede its progress. The rapidly evolving landscape of cancer treatment and diagnostics presents challenges in keeping pace with new developments. The emergence of novel biomarkers and therapies requires continuous updates and adaptations to existing companion diagnostics, which may strain resources and lead to market fragmentation. Additionally, the high costs associated with developing and validating companion diagnostics can hinder the entry of smaller players into the market, potentially limiting innovation and competition. The complex regulatory landscape surrounding companion diagnostics may also pose challenges, as compliance with evolving regulations requires substantial investments of time and capital. Furthermore, the potential for misinterpretation of test results, leading to inappropriate treatment decisions, raises concerns about the reliability and accuracy of companion diagnostics, which could undermine trust among healthcare providers and patients alike.

Another concern for the companion diagnostics market is the potential for reimbursement challenges. As healthcare systems grapple with rising costs, the reimbursement landscape for companion diagnostics may become increasingly complex. Payers may question the value of these tests in terms of improved patient outcomes, leading to potential barriers in coverage and access. If reimbursement for companion diagnostics is limited, it could dissuade healthcare providers from utilizing these tests, ultimately impacting patient care. Furthermore, the competitive landscape for companion diagnostics is intensifying, with numerous companies vying for market share. Established players may face pressure from emerging competitors offering innovative solutions at lower costs, which could lead to pricing wars and margin erosion. Overall, these threats require ongoing vigilance and strategic planning to navigate effectively.

Competitor Outlook

• Roche Diagnostics
• Thermo Fisher Scientific
• Abbott Laboratories
• Agilent Technologies
• Illumina, Inc.
• Qiagen N.V.
• Myriad Genetics, Inc.
• Guardant Health
• Foundation Medicine, Inc.
• Biocartis
• NeoGenomics Laboratories
• Exosome Diagnostics
• Freenome
• Exact Sciences Corporation
• Horizon Discovery Group plc

The competitive landscape of the companion diagnostics market for oncology is characterized by a mix of established players and emerging companies, all vying for a share of this rapidly growing market. Major companies like Roche Diagnostics and Thermo Fisher Scientific lead the way, leveraging their extensive expertise in diagnostics and robust product portfolios. These companies invest heavily in research and development to stay ahead of the curve, continuously innovating to meet the evolving needs of healthcare providers and patients. Additionally, collaborations and partnerships between these major players and smaller biotech firms are fostering advancements in companion diagnostics, allowing for the rapid introduction of new tests and technologies that cater to diverse cancer types. As the market evolves, the importance of strategic alliances to enhance product offerings and expand market reach becomes increasingly evident.

Illumina, Inc. has emerged as a significant player in the field of next-generation sequencing technologies, providing comprehensive genomic profiling solutions that are integral to companion diagnostics. Their commitment to innovation has positioned them favorably within the oncology landscape, as they continue to develop cutting-edge platforms that enhance the accuracy and efficiency of cancer diagnostics. Similarly, Guardant Health and Foundation Medicine, Inc. are at the forefront of liquid biopsy tests, providing non-invasive options for tumor profiling that are gaining traction among clinicians. These companies are capitalizing on the growing demand for precision medicine by offering solutions that simplify the process of biomarker testing while ensuring reliable results.

Emerging players such as Myriad Genetics, Exosome Diagnostics, and Freenome are also making waves in the companion diagnostics landscape, focusing on novel approaches that address unmet clinical needs. These companies are developing innovative tests that leverage advanced technologies, such as artificial intelligence and machine learning, to improve the speed and accuracy of diagnostic results. Additionally, the competitive dynamics among these companies are fostering a spirit of innovation, as they seek to differentiate their products in a crowded marketplace. As the companion diagnostics for oncology market continues to expand, the interplay between established players and new entrants will shape its future trajectory, driving advancements in cancer care and patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Freenome
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Biocartis
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Qiagen N.V.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Illumina, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Guardant Health
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Exosome Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Agilent Technologies
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Myriad Genetics, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 NeoGenomics Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Thermo Fisher Scientific
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Foundation Medicine, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Exact Sciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Horizon Discovery Group plc
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Companion Diagnostics for Oncology Market, By Application
    • 6.1.1 Breast Cancer
    • 6.1.2 Lung Cancer
    • 6.1.3 Colorectal Cancer
    • 6.1.4 Melanoma
    • 6.1.5 Others
  • 6.2 Companion Diagnostics for Oncology Market, By Distribution Channel
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Laboratories
    • 6.2.3 Research Institutes
    • 6.2.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Companion Diagnostics for Oncology Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Companion Diagnostics for Oncology market is categorized based on

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Others

By Distribution Channel

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Thermo Fisher Scientific
• Abbott Laboratories
• Agilent Technologies
• Illumina, Inc.
• Qiagen N.V.
• Myriad Genetics, Inc.
• Guardant Health
• Foundation Medicine, Inc.
• Biocartis
• NeoGenomics Laboratories
• Exosome Diagnostics
• Freenome
• Exact Sciences Corporation
• Horizon Discovery Group plc